ENZO BIOCHEM INC·4

May 30, 5:20 PM ET

HARBERT MANAGEMENT CORP 4

4 · ENZO BIOCHEM INC · Filed May 30, 2019

Insider Transaction Report

Form 4
Period: 2019-05-28
Transactions
  • Purchase

    Common Stock, $0.01 par value ("Common Stock")

    2019-05-28$3.10/sh+50,000$155,0005,117,219 total(indirect: See footnote)
  • Purchase

    Common Stock

    2019-05-29$3.08/sh+19,050$58,6745,149,946 total(indirect: See footnote)
  • Purchase

    Common Stock

    2019-05-28$3.06/sh+13,677$41,8525,130,896 total(indirect: See footnote)
  • Purchase

    Common Stock

    2019-05-30$3.07/sh+19,391$59,5305,169,337 total(indirect: See footnote)
Footnotes (1)
  • [F1]The securities reported herein are held by Harbert Discovery Fund, LP (the "Discovery Fund") and Harbert Discovery Co-Investment Fund I, LP (the "Discovery Co-Investment Fund" and together with the Discovery Fund, the "Funds"). Harbert Discovery Fund GP, LLC ( the "Discovery Fund GP") is the general partner of the Discovery Fund, and Harbert Discovery Co-Investment Fund I GP, LLC is the general partner of the Discovery Co-Investment Fund (and together with Harbert Discovery Fund GP, the "Fund GPs"). Harbert Fund Advisors, Inc. is the investment adviser to the Funds. Harbert Management Corporation ("HMC") is the managing member of the Fund GPs. Jack Bryant is a Senior Advisor to the Discovery Fund, and a Vice President and Senior Managing Director of HMC. Kenan Lucas is the managing director and portfolio manager of the Funds. Raymond Harbert is the controlling shareholder, Chairman and Chief Executive Officer of HMC.

Documents

1 file
  • 4
    ownership.xmlPrimary